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Purpose: To describe the clinical course of a patient with non-infectious idiopathic unilateral panuveitis
and retinal vasculitis treated with subcutaneous repository adrenocorticotropic hormone (ACTH) gel.
Observations: A 33-year-old male presented with blurry vision and ﬂoaters in the left eye (OS). The best-
corrected visual acuity was 20/20 in the right eye (OD) and 20/50 in OS at the time of initial presentation.
Slit-lamp examination revealed mild anterior segment inﬂammation in OS. There were 1 þ vitreous haze
and 2 þ cells noted in OS. Clinical examination and ancillary imaging assessment including ﬂuorescein
angiography revealed retinal vasculitis and optic nerve head inﬂammation. After infectious etiologies
were ruled out, the patient was started on oral corticosteroids and enrolled in a clinical trial employing
intravenous tocilizumab therapy. Six months after completion of the tocilizumab trial, the patient
demonstrated recurrence of disease. Twice weekly subcutaneous ACTH gel was initiated and the patient
demonstrated improvement of retinal vascular inﬂammation.
Conclusions and importance: Repository subcutaneous ACTH gel formulation may be a safe and viable
therapeutic option for patients with non-infectious uveitis and retinal vasculitis. Clinical trials using this
formulation in a larger patient cohort with longer monitoring are indicated to evaluate its tolerability and
bioactivity.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Due to the heterogeneity in the clinical features, etiology,
pathophysiology, and complications, management of uveitis poses
a great challenge for clinicians. Inﬂammation involving all the
compartments of the eye, i.e. panuveitis, may often result in severe
visual loss due to associated pathologies such as macular edema,
retinal vasculitis, and optic neuritis.1,2 Active research directed to-
wards effective control of inﬂammation had led to the discovery of
several pathways responsible for inﬂammatory cascade leading to
uveitis. Besides corticosteroids, a number of agents such as siroli-
mus,3 IL-1 (gevokizumab), IL-6 (tocilizumab) and IL-17 (secukinu-
mab) inhibitors, among others,4 are being explored and revisited to
determine their role in the management of uveitis.
One such agent, adrenocorticotropic hormone (ACTH), is part of
a group of molecules called melanocortins (a, b, g-melanocyteuyen).
Inc. This is an open access article ustimulating hormone; MSH) that are produced endogenously in the
hypothalamo-pituitary axis.5,6 However, it has been recently
demonstrated that melanocortins such as a-MSH can be produced
by macrophages at the site of active inﬂammation in order to
counteract the effects of pro-inﬂammatory cytokines.7 In addition
to the local autocrine effects, ACTH and other melanocortins play a
role in suppressing inﬂammation by stimulation of adrenal glands
leading to the production of glucocorticoids.8,9 Evidence suggests
that various additional anti-inﬂammatorymechanisms of actions of
ACTH may exist.9
ACTH gel was approved by United States Food and Drug
Administration (FDA) for a wide range of inﬂammatory conditions
including uveitis. ACTH gel has been reported to be effective in
systemic inﬂammatory diseases such as nephrotic syndrome,
multiple sclerosis, opsoclonus myoclonus, systemic lupus erythe-
matosus, dermatomyositis and polymyositis.10e17 However, due to
the relatively scarce data from clinical trials, ACTH has been rarely
employed in uveitis practice. The index case report describes the
potential role of subcutaneously administered ACTH gel in thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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niﬁcant retinal vasculitis, macular edema, and optic nerve
inﬂammation.2. Case report
A 33-year-old Caucasian man presented in June 2014 with
painless blurring of vision and ﬂoaters in the left eye (OS) for the
past two years. Therewas no systemic history of anymajor illnesses
and family history was non-contributory. The patient denied pre-
vious history of trauma or surgery. On ocular examination, the Early
Treatment Diabetic Retinopathy Study (ETDRS) best-corrected vi-
sual acuity (BCVA) was 20/15 in the right eye (OD) and 20/50 in OS.
Pupillary reactions were normal. Slit-lamp examination revealed
presence of 0.5 þ cells and 1 þ ﬂare in OS and quiet anterior
chamber in OD. There was presence of 2 þ vitreous haze and
2 þ vitreous cells in OS whereas examination of OD was normal.
Intraocular pressure (IOP) was normal in both eyes (OU).
In June 2014, dilated fundus examination revealed no abnor-
mality in OD. In OS, there was mild blurriness of the optic disc
margins especially nasally. However, the color and size of the disc
appeared normal. The foveal reﬂex appeared dull. There were focal
areas of perivascular sheathing predominantly involving the veins
in OS. There were no visible hemorrhages and the caliber and
contour of the vessels appeared normal (Fig. 1). Careful examina-
tion with indirect ophthalmoscopy revealed presence of snow balls
inferiorly in OS. Fluorescein angiography (FA) was performed using
the ultra-wide ﬁeld retinal camera (Optos P200Tx, Optos Inc.,
Scotland, UK). While there were no perfusion abnormalities noted
in OD, FA revealed diffuse, extensive perivenular leakage in the
posterior pole extending up to the periphery in OS. In the macular
region of OS, there was leakage temporal to the fovea. Subtle per-
ifoveal leakage was also observed. There was early disc hyper-
ﬂuorescence which persisted in the late phase suggestive of optic
nerve head inﬂammation (Fig. 1). Spectral-domain optical coher-
ence tomography (SD-OCT) revealed presence of macular edema in
OS and normal ﬁndings in OD (Fig. 2).Fig. 1. Ultra-wide ﬁeld fundus photography (AeC) and ﬂuorescein angiography (FA) of the p
eye (A) did not reveal any abnormalities. Examination of the left eye (B) reveals blurring o
square in C), and a dull foveal reﬂex. FA of the left eye (right eye not shown) in the early pha
In the late phase (E), there is diffuse perivenular leakage extending up to the periphery, peLaboratory evaluation of the patient revealed elevated eryth-
rocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels.
Complete blood counts and peripheral blood smears were normal.
The tuberculin skin test was negative. Assays for anti-nuclear
cytoplasmic antibody (ANCA), ﬂuorescent treponemal antibody
absorption (FTA-ABS) test, Lyme disease serology, anti-nuclear
antibody (ANA), anti-double stranded DNA (anti-dsDNA), and
serum lysozyme/angiotensin converting enzyme assays were un-
remarkable. Serology for HIV and titers for toxoplasmosis was
negative. Chest radiography was performed and revealed no ab-
normalities. The patient was diagnosed with unilateral idiopathic
panuveitis with retinal vasculitis and optic nerve inﬂammation and
macular edema.
Due to extensive vascular leakage and the elevated serum CRP
and ESR, which might suggest presence of systemic-wide in-
volvements, systemic therapies were considered. The patient was
started on systemic corticosteroids (oral prednisone 40 mg/day)
and topical prednisolone 1% three times a day in OS. Following
initiation of oral corticosteroids, there was interval improvement in
vitritis and retinal vascular leakage. The BCVA improved to 20/40 in
OS. In order to wean the patient off from oral corticosteroids,
initiation of immunosuppressive therapy was planned. Thus, in July
2014, he was enrolled in a clinical trial (the STOP-Uveitis Study18)
which evaluates two different doses of intravenous tocilizumab
(TCZ), an interleukin (IL)-6 inhibitor for non-infectious uveitis. The
patient was randomized to receive monthly 8mg/kg dose
(mandatory infusions up to 6 months followed by as needed
approach) of TCZ beginning July 2014. There was signiﬁcant
improvement in retinal vascular leakage and optic nerve head
hyperﬂuorescence during the course of treatment with tocilizu-
mab. Vitritis and anterior segment inﬂammation resolved. At
month 12 end-of-study (July 2015) visit, the ETDRS BCVA improved
to 20/20 in OS with resolution of macular edema (Fig. 3).
Six months after completion of the STOP-Uveitis study (January
2016), the patient presented with mild blurring of vision. Snellen
BCVA was recorded as 20/20 in OS. There were 2 þ vitreous cells
and 1 þ vitreous haze, recurrence of signiﬁcant, diffuse perivenular
leakage, and optic nerve hyperﬂuorescence on FA (Figs. 3B and 4A).atient diagnosed with panuveitis and retinal vasculitis. Fundus examination of the right
f optic disc margins, focal periphlebitis (magniﬁed area demarcated by white dashed
se (D) shows mild early disc hyperﬂuorescence and subtle leak in the temporal macula.
rifoveal leakage, and disc hyperﬂuorescence.
Fig. 2. Spectral-domain optical coherence tomography of both eyes of the patient shows normal anatomy of the retinal layers in the right eye (A) and cystoid macular edema in the
left eye (B). The external limiting membrane and outer retinal layers appear normal.
Fig. 3. Ultra-wide ﬁeld ﬂuorescein angiography (FA) of the left eye at 12 months (July 2015) after being in the clinical trial evaluating intravenous tocilizumab (A). In comparison
with the FA at the time of presentation (Fig. 1D, 1E), there is signiﬁcant decrease in the amount of vascular leakage and perifoveal leak. Six months after exiting from the tocilizumab
study (January 2016), there is recurrence of the retinal vasculitis with signiﬁcant perivenular leakage and disc hyperﬂuorescence (B).
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tocilizumab because of denial for coverage of tocilizumab for uve-
itis by his insurance. At this time, the patient was treated with H.P.
Acthar® Gel (repository corticotropin injection; Mallinckrodt
Pharmaceuticals, St. Louis, MO) (80 units administered subcuta-
neously twice weekly). Six weeks following treatment with corti-
cotropin (March 2016), there was substantial reduction in retinal
vascular leakage. There was an interval decrease in the optic nerve
head hyperﬂuorescence (Fig. 4B) as well. Vitritis resolved and BCVA
continued to remain 20/20. IOP was recorded as normal (14 mm
Hg). Due to satisfactory clinical response, currently, the patient is
being continued on treatment with repository corticotropin gel
injections.3. Discussion
The use of ACTH therapy was approved by the US FDA in 1952
for the management of various ocular inﬂammatory conditions
including posterior uveitis and choroiditis. However, since this
agent was administered either intravenously or through an intra-
muscular route, the amount of drug delivered systemically wasrelatively high resulting in severe undesirable steroid-related sys-
temic adverse effects.19 Moreover, ACTH was used only as a mon-
otherapy for the more severe forms of uveitis such as sympathetic
ophthalmia,20,21 Behçet's disease,22 and Vogt-Koyanagi-Harada
disease,23 among others. Therefore, due to various reasons, ACTH
did not gain popularity in the management of uveitis and has been
largely ignored in the recent literature.
In 1970, DeVoe, in the thesis for the American Ophthalmological
Society, described the use of intravenous ACTH in a patient with
sympathetic ophthalmia with adequate control of inﬂammation
but prompt recurrence on cessation of therapy. However, the pa-
tient developed multiple features of Cushing's syndrome and
osteoporotic fractures necessitating an alternate therapy.21 More
recently, in 1973, Aggarwal reported the use of ACTH in a patient
with Behçet's disease associated with Bell's palsy. The author
described improvement in the course of uveitis and decrease in the
recurrence of Bell's palsy following ACTH administration.22
Presently, ACTH is available as H.P. Acthar gel, a highly puriﬁed
sterile preparation in 16% gelatin to provide a prolonged release
after intramuscular or subcutaneous injection. A ﬁxed dose of ACTH
gel demonstrates a linear increase in adrenocortical secretion with
Fig. 4. Ultra-wide ﬁeld ﬂuorescein angiography (FA) and spectral-domain optical coherence tomography (SD-OCT) of the left eye prior to initiation of subcutaneous repository
corticotropin gel (A and C) and six weeks after therapy (B and D). Prior to subcutaneous corticotropin gel therapy, there is signiﬁcant active retinal vasculitis with leakage and
macular edema on FA and OCT. Within 6 weeks, there is decrease in retinal venular leakage and resolution of disc hyperﬂuorescence and macular edema on FA and OCT.
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ACTH gel has been shown to bind with all the melanocortin re-
ceptors with high afﬁnity resulting in inhibition of leukocyte
transmigration, reduction of cytokine synthesis and generation of
anti-inﬂammatory signals locally at the site of inﬂammation.24 In
addition, inhibition of nuclear factor-kB (NF-kB) decreases the
expression of various pro-inﬂammatory cytokines, receptors,
adhesion molecules and chemokines reducing the inﬂamma-
tion.25e27 Experimental studies in mice with experimental auto-
immune uveitis have shown that binding of ACTH with
melanocortin receptors is associated with recovery from the dis-
ease.28,29 Since uveitis may have a chronic clinical course, therapy
with ACTH gel should be individualized. Long-term therapy with
ACTH gel may be needed in patients with multiple recurrences. The
limitations of the use of ACTH gel in uveitis include high cost of
therapy, which may make the agent less available for many pa-
tients. ACTH gel is contraindicated in patients with systemic fungal
infections, ocular herpes, peptic ulcer, uncontrolled hypertension,
recent surgery, congestive cardiac failure, or osteoporosis. The
adverse effects of ACTH gel can be similar to systemic corticoste-
roids and include ﬂuid retention, altered electrolyte balance, in-
crease in blood glucose, systemic hypertension, mood changes,
weight gain, Cushingnoid features, among others.30
In the index case, adequate control of inﬂammation and retinal
vasculitis was achieved following the use of intravenous tocilizu-
mab. However, 6 months after the patient completed the clinical
trial employing tocilizumab, there was a recurrence of the disease
(Fig. 3). At this time, given the young age of the patient and elevated
biomarkers for systemic involvements, as well as the possibility of
ocular side-effects with local steroid therapy, a systemic agent for
the treatment of the recurrence was preferred. Therapy with ACTH
gel resulted in rapid and adequate control of retinal vascular
leakage, macular edema and optic nerve inﬂammation (Fig. 4).
With ﬁxed interval administration and slow release of ACTH, sup-
pression of hypothalamo-pituitary axis is not expected in our pa-
tient. At the end of 6 weeks, there were no safety concerns and no
systemic or local (dermal or ocular) adverse events were recorded.
Thus, the patient is being continued on ACTH gel therapy with close
monitoring for possible steroid-related side-effects.4. Conclusions
Although rarely employed in ophthalmology practice thus far,
subcutaneous repository ACTH gel may have a role in the man-
agement of certain uveitic entities such as retinal vasculitis. Short-
term follow-up of our patient shows that the onset of drug action is
rapid following subcutaneous administration. Potential advantages
of this therapy include relatively easier route of administration, no
need for daily therapy, and predictable course of action. However,
careful monitoring and long-term follow-up are warranted to
detect steroid-related adverse events early. The ﬁndings in our
index patient encourage future clinical trials employing repository
corticotropin injection in the management of uveitis.Patient consent
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